MAPK8 and chronic myelogenous leukemia, BCR-ABL1 positive: Although activation of MET and JNK is not reported to be associated with BCR-ABL1-independent imatinib resistance in CML patients, there are indications that ABL1 interacts with oncogenic MET [30].